<DOC>
	<DOCNO>NCT02895672</DOCNO>
	<brief_summary>This real-world , pre-post observational study ambulatory endocrinology practice determine effectiveness safety addition glucagon-like peptide-1 ( GLP-1 ) agonist therapy ( weekly exenatide { Bydureon } daily liraglutide { Victoza } ) , add regimen T2DM patient already receive minimum one year basal insulin therapy . Specifically , investigator hypothesize GLP-1 agonist therapy add basal insulin therapy result statistically significant improve glycemic control weight loss , high risk hypoglycemia compare baseline .</brief_summary>
	<brief_title>GLP-1/Basal Insulin Combination Therapy</brief_title>
	<detailed_description>This pre-post observational study ass efficacy safety 12 month GLP-1 therapy add therapeutic regimen group T2DM patient . This study review approve Albany College Pharmacy Health Sciences Institutional Review Board . Potential subject identify via computerized text search medication problem field patient electronic medical record ( EMR ) . Search term include exenatide , Bydureon , liraglutide , Victoza , GLP-1 agonist , NPH , Lantus , Levemir , T2DM . Individual record identify patient review ascertain applicable study criterion meet . Inclusion criterion : T2DM , age 18-85 year , documentation basal insulin therapy minimum one year prior GLP-1 initiation , addition weekly exenatide daily liraglutide add basal insulin therapy minimum 12 month . Exclusion criterion include : Type 1 diabetes , patient receive prescription medication weight loss , initiation additional diabetes , hypertension cholesterol drug follow-up period . A data collection form utilized collect follow patient information : baseline demographic information ( gender , age , height , weight ) , duration diabetes , medication , laboratory information ( HbA1C , cholesterol profile [ total cholesterol , triglyceride , LDL-C , HDL-C ] ) , blood pressure . The primary study outcome change HbA1C baseline 12 month GLP-1 therapy add basal insulin therapy . A separate analysis include patient complete 12 month GLP-1 therapy also perform . Secondary outcome change weight , percentage patient achieve A1C &lt; 7 % , change systolic diastolic blood pressure , change lipid parameter ( TC , LDL-C , HDL-C , TG 's ) , reduction number/doses diabetes , blood pressure , lipid lower medication . Safety assess collection report adverse effect . Medication compliance assess review insurance data base record refill .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>T2DM , age 1885 year , documentation basal insulin therapy minimum one year prior GLP1 initiation , addition weekly exenatide daily liraglutide add basal insulin therapy Type 1 diabetes , patient receive prescription medication weight loss , initiation additional diabetes , hypertension cholesterol drug followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>